Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:603707'
s Interest Coverage Range Over the Past 10 Years
Min: 9.95 Med: 17.41 Max: 97.37
Current: 9.95
SHSE:603707's Interest Coverage is ranked worse than 54.44% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.7
vs SHSE:603707: 9.95
Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Nanjing King-Friend Biochemical Pharmaceutical Co Interest Coverage Related Terms
Nanjing King-Friend Biochemical Pharmaceutical Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Nanjing King-Friend Biochemical Pharmaceutical Co Interest Coverage Chart
Nanjing King-Friend Biochemical Pharmaceutical Co Annual Data
SHSE:603707 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nanjing King-Friend Biochemical Pharmaceutical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing King-Friend Biochemical Pharmaceutical Co Interest Coverage vs Drug Manufacturers Industry
Nanjing King-Friend Biochemical Pharmaceutical Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) has a Interest Coverage of 6.20 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Nanjing King-Friend Biochemical Pharmaceutical Co and its competitors. This is 64% below median its historical median of 17.41. Over the past decade, Nanjing King-Friend Biochemical Pharmaceutical Co's Interest Coverage has ranged from 9.95 to 97.37. According to the industry distribution chart, Nanjing King-Friend Biochemical Pharmaceutical Co ranks #374 out of 687 companies in the Drug Manufacturers industry, placing it in the top 54.4%.
Is Nanjing King-Friend Biochemical Pharmaceutical Co's Interest Coverage too high?
Nanjing King-Friend Biochemical Pharmaceutical Co's current Interest Coverage of 6.20 is 64% below median its 10-year median of 17.41. Over the past 10 years, this metric has ranged from a low of 9.95 to a high of 97.37. The Drug Manufacturers industry median Interest Coverage is 12.70. Nanjing King-Friend Biochemical Pharmaceutical Co's value of 6.20 is 51.2% below this industry median. Based on the distribution chart, Nanjing King-Friend Biochemical Pharmaceutical Co ranks #374 out of 687 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Nanjing King-Friend Biochemical Pharmaceutical Co has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanjing King-Friend Biochemical Pharmaceutical Co's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nanjing King-Friend Biochemical Pharmaceutical Co ranks #374 out of 687 companies for Interest Coverage. This places Nanjing King-Friend Biochemical Pharmaceutical Co in the lower half of its industry. The industry median Interest Coverage is 12.70. Nanjing King-Friend Biochemical Pharmaceutical Co's value of 6.20 is 51.2% below this benchmark. Historically, Nanjing King-Friend Biochemical Pharmaceutical Co's own Interest Coverage has ranged from 9.95 to 97.37 over the past decade. While the company's 10-year median is 17.41 vs. the industry median of 12.70, Nanjing King-Friend Biochemical Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.70, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing King-Friend Biochemical Pharmaceutical Co's current Interest Coverage of 6.20 is 51.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Nanjing King-Friend Biochemical Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing King-Friend Biochemical Pharmaceutical Co's current Interest Coverage is 6.20, which is 64% below median its own 10-year median of 17.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing King-Friend Biochemical Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥12.70, compared to a current price of ¥7.55 — trading 40.6% below its estimated fair value. The current Interest Coverage is 6.20, which is 64% below median its 10-year median of 17.41 and 51.2% below the Drug Manufacturers industry median of 12.70. Nanjing King-Friend Biochemical Pharmaceutical Co's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707), the current Interest Coverage is 6.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing King-Friend Biochemical Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥7.55 is trading 40.6% below its estimated GF Value™ of ¥12.70.
GuruFocus considers Nanjing King-Friend Biochemical Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:603707:
Interest Coverage: 6.20 (64% below median its 10-year median of 17.41)
GF Value™: ¥12.70 vs. price of ¥7.55 (40.6% below fair value)
Industry Position: 51.2% below the Drug Manufacturers median (#374 of 687)
No single metric tells the full story. See the SHSE:603707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanjing King-Friend Biochemical Pharmaceutical Co Business Description
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.
65GF Score
Get the complete analysis for SHSE:603707
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603707 has been successfully added to your 
